|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005330,
umls-concept:C0006560,
umls-concept:C0016006,
umls-concept:C0020474,
umls-concept:C0030705,
umls-concept:C0032105,
umls-concept:C0032143,
umls-concept:C0082608,
umls-concept:C0087111,
umls-concept:C0205195,
umls-concept:C0441889,
umls-concept:C1280500,
umls-concept:C1420522,
umls-concept:C1956346,
umls-concept:C1999216,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2000-7-31
|
|
pubmed:abstractText |
We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed hyperlipidaemia.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bezafibrate,
http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Monounsaturated,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA...,
http://linkedlifedata.com/resource/pubmed/chemical/Hypolipidemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator,
http://linkedlifedata.com/resource/pubmed/chemical/fluvastatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0340-6245
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
83
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
549-53
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10780315-Adult,
pubmed-meshheading:10780315-Aged,
pubmed-meshheading:10780315-Bezafibrate,
pubmed-meshheading:10780315-C-Reactive Protein,
pubmed-meshheading:10780315-Cholesterol, LDL,
pubmed-meshheading:10780315-Coronary Disease,
pubmed-meshheading:10780315-Double-Blind Method,
pubmed-meshheading:10780315-Drug Synergism,
pubmed-meshheading:10780315-Drug Therapy, Combination,
pubmed-meshheading:10780315-Fatty Acids, Monounsaturated,
pubmed-meshheading:10780315-Female,
pubmed-meshheading:10780315-Fibrinogen,
pubmed-meshheading:10780315-Humans,
pubmed-meshheading:10780315-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:10780315-Hyperlipidemia, Familial Combined,
pubmed-meshheading:10780315-Hyperlipoproteinemia Type II,
pubmed-meshheading:10780315-Hypertriglyceridemia,
pubmed-meshheading:10780315-Hypolipidemic Agents,
pubmed-meshheading:10780315-Indoles,
pubmed-meshheading:10780315-Male,
pubmed-meshheading:10780315-Middle Aged,
pubmed-meshheading:10780315-Tissue Plasminogen Activator,
pubmed-meshheading:10780315-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
|
|
pubmed:affiliation |
University of Milan, Italy. centrorc@mailserver.unimi.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
